Pharma RSS Digest - 2026-05-13
Overview
The May 13 session produced a light news cycle with two substantive developments spanning regulatory advancement in oncology and a consumer health safety recall. The dominant theme tilted toward pipeline and platform news rather than landmark clinical data, with signal emerging primarily from wire services and FDA announcements. China's Kelun-Biotech secured parallel regulatory clearance for a bispecific antibody candidate, enabling synchronized development across the world's two largest pharmaceutical markets, while a Wisconsin manufacturer pulled an over-the-counter eczema treatment over microbial contamination. The tape offered little broader sector direction, leaving investors to parse company-specific catalysts in an otherwise quiet session.
Key Developments
Kelun-Biotech won CDE IND approval for SKB118, a bispecific antibody targeting PD-1 and VEGF for advanced solid tumors. The May 12 clearance from China's Center for Drug Evaluation grants Kelun-Biotech the ability to conduct parallel clinical trials in China alongside the global ASCEND Phase I/II trial already initiated in the U.S. in January. The company acquired exclusive Greater China rights to SKB118 (also designated CR-001) from Crescent Biopharma in December 2025 and is positioning the candidate within an "ADC+IO" strategy, leveraging the dual mechanism—PD-1 blockade to restore T-cell tumor recognition and VEGF inhibition to normalize tumor vasculature—to potentially enhance delivery of its proprietary ADC assets. Early clinical data readouts from the ASCEND trial, which plans to enroll up to 290 patients, will be the next meaningful inflection point.
Kelun-Biotech fda approval update
Pharmacal issued a nationwide recall of MG217 Multi-Symptom Treatment Cream after internal testing detected Staphylococcus aureus in a single lot. The recall covers lot 1024088 (expiration November 2026) of the 6-oz eczema cream distributed through wholesale channels, HE-BUTT Grocery, and Amazon, with the FDA posting the notice on May 12. No adverse events have been reported, though the contaminant poses infection risk—particularly for immunocompromised users who could develop serious skin, soft-tissue, or systemic complications. The recall surfaces manufacturing quality concerns for topical OTC products and may invite increased FDA scrutiny of the Jackson, Wisconsin facility. Stakeholders should watch for any expansion of the recall to additional lots or regulatory action stemming from the investigation.
Watchlist
- No additional items met threshold for inclusion in today's session. [link]